Skip to main content

Table 2 Best overall response according to RECIST

From: Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR

Parameter

PCG arm (%) (N = 43)

PC arm (%) (N = 43)

Odds ratio (95 % CI)

P-value

Objective response

18 (41.9)

17 (39.5)

0.91

0.826

95 % CI

(27.0–57.9)

(25.0–55.6)

(0.38–2.13)

 

Disease control

32 (74.4)

28 (65.1)

0.64

0.348

95 % CI

(58.8–86.5)

(49.1–79.0)

(0.25–1.61)

 

Complete response

0 (0)

0 (0)

  

Partial response

18 (41.9)

17 (39.5)

  

Stable disease

14 (32.6)

11 (25.6)

  

Progressive disease

10 (23.3)

13 (30.2)

  

Missing

1 (2.3)

2 (4.7)

  
  1. N number; CI confidence interval